Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Post by forhandlarenon Jun 05, 2019 5:35pm
367 Views
Post# 29801048

Additional gains for the days/weeks/months to come

Additional gains for the days/weeks/months to comeI find it hard to calculate a value of the proprietary platform as an isolated entity, but for sure it's substantial. Versatile and disruptive! Pharmaceuticals and cosmetics. Nevertheless, it has been long overdue for the share price to start to reflect the value - including the existing SGLT2 deal of course. Great that there's a gain folllowed by accumulation before next gain. In this way the share price will be sustainable.

Must say that based in the last interview I don't expect the first Skin Lightening deal in the very near future - but probably before the summer is over and it could be as many as 4-5 deals altogether.

In the meantime I expect an Wanbang SGLT2 update and maybe something additional from them as Howard has indicated. The results from the second TFC-1067 trial in China should be due very soon. We might also get at least an update, if not another deal, on SGLT2 for pets.

I would be surprised if the share price is below 2 bucks before the end of the autumn.
Bullboard Posts